AlphAIAlphAI — Financial news for AI agents
prnewswire.comMAY 294 min read$ATNM

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Actinium Pharmaceuticals (NYSE American: ATNM) said it will present new ATNM-400 (Actinium-225 antibody radioconjugate) data at SNMMI 2026 in Los Angeles May 30–June 2, with three posters on prostate cancer, NSCLC, and radioconjugate optimization. Separately, NYSE American notified the company it is not in compliance with $4.0m stockholders’ equity requirements; Actinium must submit a compliance plan by June 26, 2026.

Original reporting
prnewswire.com
Published May 29, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 10:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice — source image
Source · prnewswire.com
Decision brief

The 30-second read

$ATNMNeutralMed
01

Why it matters

The release combines (1) scheduled scientific updates at SNMMI with (2) a procedural exchange-risk timeline that can drive risk premia and liquidity concerns even without immediate delisting action.

02

Market read

Traders may weigh a near-term risk premium from potential delisting proceedings against incremental event-driven interest ahead of SNMMI data.

03

What to watch

Market reaction may hinge less on the SNMMI posters themselves and more on whether the compliance plan details are credible and whether equity financing is implied/needed.

Relevance 9/10Novelty 6/10Timing: Into SNMMI 2026 (May 30–June 2) and ahead of the June 26, 2026 compliance-plan deadline.

Background

Actinium is a targeted radiotherapies company developing Actinium-225 antibody radioconjugates (notably ATNM-400) and received an NYSE American notice for continued listing standards related to stockholders’ equity and net losses.

Company-level read

Ticker impact

$ATNMNeutralMedium confidence
Context

Actinium (ATNM) announced SNMMI 2026 ATNM-400 program updates and disclosed an NYSE American continued-listing standards non-compliance notice.

Expected impact

Near-term volatility risk from delisting headlines; incremental upside possible into SNMMI as investors price in clinical-read-through.

Evidence & confidence

The listing notice has explicit procedural timelines (plan due June 26, 2026; potential delisting by Nov 27, 2027) while the SNMMI update is promotional but time-specific for data delivery.

Market effects

Sector

Highlights ongoing capital-market/listing risk for pre-commercial biotech while reinforcing investor focus on Actinium-225 radioconjugate platform read-through.

Regional

Primarily US microcap/small-cap sentiment via NYSE American listing-risk mechanics.

Global

Limited; conference data and exchange compliance are US-specific though radiopharma interest is global.

Counterpoint

What could challenge this read

The notice has 'no immediate effect' on trading; investors may over-discount delisting risk if the company submits an acceptable plan.

Key entities

  • issuer
    Actinium Pharmaceuticals, Inc.

    Subject of the press release; provides ATNM-400 SNMMI 2026 presentation details and discloses NYSE American listing standards non-compliance notice.

  • exchange
    NYSE American LLC

    Issued the continued listing standards non-compliance notice under Section 1003(a)(ii) of the Company Guide.

  • program
    ATNM-400

    Actinium-225 antibody radioconjugate with three SNMMI 2026 presentations (prostate cancer, NSCLC, and chelator optimization).

Read at source← All news

Related articles

OCT 15
$ATNMMedAI 8/10

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Actinium Pharmaceuticals (ATNM) announced early Phase 1 trial results for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC), to be presented at EANM 2026. The study assesses safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, aiming to inform therapeutic dosing with Actinium-225-labeled ATNM-400.

prnewswire.com2 min
OCT 15
$ATNMMedAI 8/10

Some prostate cancers progress after targeted therapy. Actinium is testing radiation aimed at a different target.

Actinium Pharmaceuticals presented early Phase 1 trial data for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC). The study aims to assess safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, with plans to advance to Actinium-225-labeled therapy. According to the company, ATNM-400 targets a novel antigen and could benefit a broad mCRPC patient population, including those resistant to PSMA-directed therapies.

stocktitan.net2 min
AUG 14
$ATNMMed

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.

prnewswire.com4 min
MAY 29
$ATNMLow

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Actinium Pharmaceuticals said the Canadian Intellectual Property Office issued Notices of Allowance for two patent applications covering its Actimab-A and Iomab-ACT programs. The Actimab-A/CLAG-M AML combination allowance is expected to issue with a term into Jan. 2039; the CD45 conditioning for gene-edited cell therapies is expected to issue with a term into Oct. 2038. Actinium said this adds to a global portfolio of about 250 issued and pending patents.

prnewswire.com3 min
OCT 15
$DELLHigh

Dell stock tumbles 8% in a day. Here’s why

Dell Technologies (DELL) shares fell 8% on Thursday, following a 11% drop on Wednesday, due to investor concerns about enterprise AI spending. Barclays downgraded Dell, Hewlett Packard Enterprise (HPE), and NetApp (NTAP), citing uncertainty about AI infrastructure demand and lowering Dell's price target to $574. Despite strong Q2 earnings, Dell's stock has declined amid broader market caution about AI-related hardware spending.

finance.yahoo.com3 min